CRISM Therapeutics Provides Positive Clinical Trial Update
Why we think this is neutral
The RNS provides an update on CRISM Therapeutics' clinical trial for its ChemoSeed product, which is focused on improving the delivery of chemotherapy drugs to treat solid tumors. While the update is positive, with the MHRA providing favorable feedback on the trial design, this type of news is not one of the mandatory categories that would warrant a more detailed analysis. Therefore, a neutral sentiment score is appropriate.
Key Points
- MHRA provided positive written scientific advice on ChemoSeed clinical trial programme
- Further preclinical toxicology studies not required, reducing development costs and timelines
- Company progressing MHRA recommendations and expects to submit CTA application in H1 2025 and begin trials in Q4 2025
Summary
CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery company, has received positive written scientific advice from the MHRA on the development, clinical trial programme and potential Market Authorisation Application for the commercialisation of its lead product, ChemoSeed. The MHRA confirmed that further preclinical toxicology studies will not be required, reducing the cost and time of the development work. The Company is now progressing the MHRA's recommendations and expects to finalise its CTA application for submission in H1 2025 and to begin clinical trials of ChemoSeed in Q4 2025.